Trametinib
Showing 1 - 25 of 253
Arteriovenous Malformations Trial (Trametinib tablet)
Not yet recruiting
- Arteriovenous Malformations
- Trametinib tablet
- (no location specified)
Oct 17, 2023
Cholangiocarcinoma Trial (GNS561 + Trametinib)
Not yet recruiting
- Cholangiocarcinoma
- GNS561 + Trametinib
- (no location specified)
May 22, 2023
Advanced or Metastatic Solid Tumors Trial (Naporafinib, Trametinib)
Not yet recruiting
- Advanced or Metastatic Solid Tumors
- Naporafinib
- Trametinib
- (no location specified)
Jun 21, 2023
Aspirin in Combination With Trametinib and Dabrafenib
Not yet recruiting
- NSCLC
- +4 more
- Combind asprin with Trametinib and Dabrafenib
- (no location specified)
Aug 4, 2023
Leukemia, Juvenile Myelomonocytic, JMML, JCML Trial (Trametinib, Azacitidine, Fludarabine)
Not yet recruiting
- Leukemia, Juvenile Myelomonocytic
- +4 more
- Trametinib
- +3 more
- (no location specified)
May 4, 2023
Healthcare Resource Utilization and Costs in Metastatic Melanoma
Terminated
- Metastatic Melanoma
-
East Hanover, New JerseyNovartis Investigational Site
Apr 27, 2023
Metastatic Malignant Tumor in the Brain Trial in Columbus (other, procedure, drug, radiation)
Active, not recruiting
- Metastatic Malignant Neoplasm in the Brain
- Laboratory Biomarker Analysis
- +4 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Oct 15, 2022
Dabrafenib Plus Trametinib In Rare BRAF V600E Mutation-Positive
Not yet recruiting
- Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
- Non-investigational
- (no location specified)
May 11, 2023
Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer Trial in Salt Lake City
Recruiting
- Metastatic Pancreatic Carcinoma
- +6 more
- Hydroxychloroquine
- Trametinib
-
Salt Lake City, UtahHuntsman Cancer Institute/University of Utah
Oct 31, 2022
BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic Carcinoma Trial in Duarte, Columbus (Dabrafenib,
Recruiting
- BRAF NP_004324.2:p.V600E
- +2 more
- Dabrafenib
- +2 more
-
Duarte, California
- +1 more
Jan 19, 2023
Colorectal Cancer, Pancreatic Adenocarcinoma Trial in Singapore (Trametinib, Ruxolitinib)
Recruiting
- Colorectal Cancer
- Pancreatic Adenocarcinoma
- Trametinib
- Ruxolitinib
-
Singapore, SingaporeNational Cancer Centre
Jun 10, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Trametinib
Active, not recruiting
- Advanced Lymphoma
- +5 more
- Trametinib Dimethyl Sulfoxide
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Aug 13, 2022
Associated Factors, and Clinical Outcomes of Prescribing
Completed
- BRAF v600 Mutated Metastatic Melanoma
-
East Hanover, New JerseyNovartis Pharmaceuticals
Mar 28, 2023
Metastatic Melanoma, BRAF Gene Mutation Trial in Lexington (Nilotinib 100mg, Nilotinib 200mg, Nilotinib 300mg)
Recruiting
- Metastatic Melanoma
- BRAF Gene Mutation
- Nilotinib 100mg
- +5 more
-
Lexington, KentuckyMarkey Cancer Center
Jul 22, 2022
Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer Trial in San Francisco (Capmatinib, Trametinib)
Recruiting
- Metastatic Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer
- Capmatinib
- Trametinib
-
San Francisco, CaliforniaUniversity of California San Francisco
Aug 15, 2022
Metastatic Colorectal Cancer Trial in Boston (Dabrafenib, Trametinib, PDR001)
Recruiting
- Metastatic Colorectal Cancer
- Dabrafenib
- +2 more
-
Boston, Massachusetts
- +1 more
Jun 24, 2022
Advanced Uveal Melanoma, Metastatic Uveal Melanoma, Unresectable Uveal Melanoma Trial (BRD4 Inhibitor PLX2853, Trametinib,
Not yet recruiting
- Advanced Uveal Melanoma
- +2 more
- BRD4 Inhibitor PLX2853
- +4 more
- (no location specified)
Jan 9, 2023
EGFR NP_005219.2:p.S492R, KRAS Gene Mutation, MAP2K1 Gene Mutation Trial in Houston (other, biological, drug)
Recruiting
- EGFR NP_005219.2:p.S492R
- +7 more
- Laboratory Biomarker Analysis
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID
Active, not recruiting
- Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
- +2 more
- Dabrafenib
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Aug 9, 2022
Histiocytosis Trial in Warsaw (Trametinib)
Recruiting
- Histiocytosis
- Trametinib
-
Warsaw, Mazovian, PolandMother and Child Institute
Aug 2, 2022
BRAF V600-mutated Lung Carcinoma Treated With Combination of
Completed
- Non Small Cell Lung Cancer
- BRAF V600 Mutation
-
Créteil, France
- +1 more
Jun 29, 2022